Mal-Pip-ValCit-PAB-AZ7550 

Mal-Pip-ValCit-PAB-AZ7550 is a prodrug of EGFR inhibitor. Mal-Pip-ValCit-PAB-AZ7550 selectively binds covalently to albumin via its maleimide moiety. Mal-Pip-ValCit-PAB-AZ7550 exhibits potent in vivo anticancer activity in non-small cell lung cancer xenograft models. Mal-Pip-ValCit-PAB-AZ7550 can be used in research related to non-small cell lung cancer^[1].

Mal-Pip-ValCit-PAB-AZ7550 (Mal-Pip-ValCit) (46 μM; 1.5 h (cleavage without albumin), 3.5 h (pre-incubation with HSA) + 4 h (cleavage)) is efficiently cleaved by cathepsin B to release OsiNHMe, and this cleavage process remains equally efficient when Mal-Pip-ValCit is pre-bound to human serum albumin^[1].
Mal-Pip-ValCit-PAB-AZ7550 (50 μM; 10 min (binding), ~10 min (NAC pre-incubation)) rapidly forms covalent bonds with human serum albumin via its maleimide group, achieving a binding rate of over 95% within 10 min at 37 °C^[1].
Mal-Pip-ValCit-PAB-AZ7550 (0.25-1.5 equivalents relative to Cys³⁴ thiol; 20 min) binds to the Cys³⁴ thiol residue of human serum albumin; after incubation at 37 °C for 20 min, the binding rate reaches 53% when the ratio of the compound to Cys³⁴ is 1:1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mal-Pip-ValCit-PAB-AZ7550 (83.7 mg/kg; i.v.; twice weekly for 2 weeks) exhibits potent in vivo anticancer activity in the H1650 non-small cell lung cancer xenograft model, delivers significant survival benefits, and results in a median survival time of 90 days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1198.37

C₆₁H₇₉N₁₅O₁₁

O=C(OCC1=CC=C(NC([C@@H](NC([C@@H](NC(CCN2CCN(CCOCCN3C(C=CC3=O)=O)CC2)=O)C(C)C)=O)CCCNC(N)=O)=O)C=C1)N(CCN(C4=CC(OC)=C(NC5=NC=CC(C6=CN(C)C7=C6C=CC=C7)=N5)C=C4NC(C=C)=O)C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Federa A, et al. Tumor-Targeted Delivery of an EGFR Inhibitor Prodrug via Site-Specific Albumin Conjugation. J Med Chem. 2026;69(3):2554-2574.  [Content Brief]